TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03719391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virginia Tobacco flavored JUUL 5% ENDS
Description: Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool Mint flavored JUUL 5% ENDS
Description: Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango flavored JUUL 5% ENDS
Description: Treatment with Mango flavored JUUL 5% ENDS (10 puffs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creme Brulee flavored JUUL 5% ENDS
Description: Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VUSE Solo e-cigarette
Description: Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette White Ice Mint 4mg nicotine polacrilex gum
Description: Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand combustible cigarette
Description: Treatment with usual brand cigarette (10 puffs).
Study: NCT03437642

Intervention type: BEHAVIORAL
Intervention: Short Term Psychotherapy
Description: Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs

Intervention type: BEHAVIORAL
Intervention: Short Term Psychotherapy
Description: Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
Study: NCT02166021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Mesenchymal stem cells
Description: A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
Study: NCT02963714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study: NCT02593747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine oral solution
Description: Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine oral solution
Description: Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Claritin peach syrup)
Description: Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Claritin peach syrup)
Description: Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
Study: NCT01557608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photon stimulation
Description: The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment.
Study: NCT04542694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 200 mg coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.
Study: NCT02228109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Presbyopia
Description: Acuvue Oasys for Presbyopia contact lenses worn

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PureVision2 for Presbyopia
Description: PureVision2 for Presbyopia contact lenses worn

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal
Description: Biofinity Multifocal contact lenses worn
Study: NCT04082806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: 50 mg/kg GHB at one experimental night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: 50 mg/kg GHB at one experimental night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 1.5 mg/kg trazodone at one experimental night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 1.5 mg/kg trazodone at one experimental night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
Study: NCT02507817

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein

Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein
Study: NCT02137382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon®
Description: active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creon N
Description: experimental drug
Study: NCT03662763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride (SPD503)
Description: dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT03907917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study: NCT03297086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
Study: NCT01647958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsophyX System with SerosaFuse fasteners
Description: Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI
Description: Control Arm participants will take maximum standard dose of PPI during Initial Study period
Study: NCT00544817

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 2 Gy/fraction, single daily fractions M-F, to 60 Gy total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
Study: NCT00686244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined 3-monthly endurance and strength training
Description: Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism
Study: NCT04047953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
Description: Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
Study: NCT00114231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT02612181

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine for dexmedetomidine group
Description: The effect of dex and placebo for sedation on microcirculation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine for dexmedetomidine group
Description: The effect of dex and placebo for sedation on microcirculation
Study: NCT01736787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cauliflower Mushroom extract
Description: Cauliflower Mushroom extract (1g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1g/day)
Study: NCT01099631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhimurium
Description: Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
Study: NCT03370822

Intervention type: DEVICE
Intervention: MONICA AN24 device
Description: Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
Study: NCT01054352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342
Description: multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: up to four (4) additional cohorts consisting of healthy male volunteers may be added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: .up to four (4) additional cohorts consisting of healthy male or female volunteers may be added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ38224342/placebo
Description: one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
Study: NCT02626104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin
Description: The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
Study: NCT02614872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLASSIA® and Institution standard of care (SOC)
Description: Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
Study: NCT02523326

Intervention type: DEVICE
Intervention: saliva samples obtained with mouthwash
Description: saliva samples obtained with mouthwash

Intervention type: DEVICE
Intervention: saliva samples obtained with mouthwash
Description: saliva samples obtained with mouthwash
Study: NCT02090764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06561802

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF and saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF and saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF and saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
Study: NCT02523326

Intervention type: DEVICE
Intervention: saliva samples obtained with mouthwash
Description: saliva samples obtained with mouthwash
Study: NCT01196169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
Study: NCT03003663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensableCare System
Description: The SensableCare System is evaluated for reducing bed falls.
Study: NCT01528592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa
Description: Equivalent amount of carbidopa-levodopa will be provide to you
Study: NCT01047540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIC316
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT01854450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetrical Lateral Decubitus
Description: After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: usual obstetrical care
Study: NCT03557853

Intervention type: DRUG
Intervention: Golimumab Injection
Description: Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
Study: NCT01949831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of functional ability in combination with follow-up at home
Study: NCT02506465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTIND
Description: Temporary Implantable Nitinol Device (iTIND)
Study: NCT00492544

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™ (HPV-16/18 L1 VLP AS04)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT01914588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: * Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits